Metabolon Closes Additional Financing

Series C Round Now Closed with a Total of $12.3 Million in Additional Capital

RESEARCH TRIANGLE PARK, N.C., October 27, 2009-- Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.

Syngenta Ventures, the corporate venture capital subsidiary of Syngenta, and Fletcher Spaght Ventures invested as new investors joining Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities as Series C investors.

As a part of the financing, Carol Marino, Ph.D., Vice President of Syngenta Ventures and Guy Fish, MD, Vice President of Fletcher Spaght will join Metabolon’s Board of Directors. Syngenta, a leading global agribusiness company, also expanded a previously announced research collaboration with Metabolon.

Metabolon offers global biochemical profiling (metabolomic) services to researchers working in drug safety and toxicology, bioprocess optimization, consumer products and other areas which benefit from insight into complex biochemical processes and how they change in response to experimental variables.

The company’s technology has been used to identify biochemical biomarkers useful for the development of a wide range of diagnostics. These markers are being applied to the development of its own proprietary diagnostic tools for prostate cancer and insulin resistance.

About Metabolon

Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.

Contact:
Metabolon, Inc.
Todd Lynch, 919-287-3368; tlynch@metabolon.com
www.metabolon.com

News Index

Venture Capital Database